Al Kawas, Hivin
Saaid, Inas
Jank, Paul
Westhoff, Christina C.
Denkert, Carsten
Pross, Therese
Weiler, Karoline Barbara Stephanie
Karsten, Maria Margarete http://orcid.org/0000-0001-7587-7550
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Accepted: 16 February 2022
First Online: 18 March 2022
Declarations
:
: No ethic approval was needed for this publication.
: Not applicable.
: All authors consented to the publication.
: Dr. Karsten reports personal fees from Roche and from Sysmex and grants from the German government for a different project outside the submitted work. Paul Jank reports a stock ownership from Myriad Genetics, Inc. outside the submitted work. Dr. Denkert reports grants from the European Commission H2020 and the German Cancer Aid Translational Oncology project during the conduct of the study, in addition to personal fees from Novartis, Roche, MSD Oncology, Daiichi Sankyo, AstraZeneca and Molecular Health. He also reports grants from Myriad, personal fees from Merck and was a cofounder and shareholder until 2016 of Sividon diagnostics. In addition, Dr. Denkert has a patent VMScope on digital pathology software with royalties paid, a patent WO2020109570A1 - cancer immunotherapy pending, and a patent WO2015114146A1 and WO2010076322A1 - therapy response issued. Apart from that, there are no conflicts of interest to disclose.